Troy A. Ignelzi, Chief Financial Officer at Karuna Therapeutics, Inc. (KRTX), sold 18,000 shares at $223.21 ($4.0M) on 2023-05-23, disclosed to the SEC on 2023-05-25.
Scheduled sale ($4.0M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $221.28 | 724 | $160K | 4.0% |
| 2 | $221.28 | 724 | $160K | 4.0% |
| 3 | $222.24 | 2,093 | $465K | 11.6% |
| 4 | $222.24 | 2,093 | $465K | 11.6% |
| 5 | $223.21 | 3,309 | $739K | 18.4% |
| 6 | $223.21 | 3,309 |
| $739K |
| 18.4% |
| 7 | $224.19 | 1,070 | $240K | 6.0% |
| 8 | $224.19 | 1,070 | $240K | 6.0% |
| 9 | $225.19 | 1,022 | $230K | 5.7% |
| 10 | $225.19 | 1,022 | $230K | 5.7% |
| 11 | $225.93 | 782 | $177K | 4.4% |
| 12 | $225.93 | 782 | $177K | 4.4% |
| Total | $223.41 avg | 18,000 | $4.0M | 100% |
| Filing → |
| KRTX | SELL | 2023-02-23 | $1.1M | — | Filing → |
| KRTX | SELL | 2023-01-19 | $369K | — | Filing → |
| KRTX | SELL | 2022-11-17 | $3.7M | — | Filing → |